The following data will be collected:~general demographic data;~time from chest pain onset to primary PCI;~comorbidities (ischemic heart disease, arterial hypertension, previous PCI or coronary artery bypass surgery - CABG, heart failure, peripheral artery disease, atrial fibrillation, stroke, diabetes mellitus, kidney disease);~cardiovascular risk factors (age, body mass index, smoking, abdominal perimeter, sedentarism, gender, inflammation);~cardiac rhythm derived from electrocardiographic data;~HRV time- and frequency domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio);~routine biological data and biomarkers, including creatine kinase-MB (CK-MB), aspartate transaminase (AST), lactate dehydrogenase (LDH) and cardiac-specific troponin;~left ventricular ejection fraction at admission, at discharge and at follow-up (1 month, 6 months and 1 year);~initial and final thrombolysis in myocardial infarction (TIMI) flow;~type of stent used for coronary angioplasty;~Global Registry of Acute Coronary Events (GRACE) score;~SYNTAX score II in case of three-vessel coronary disease or involving left main stem;~in-hospital, one month and long-term clinical outcomes (composite of all-cause mortality and major adverse cardiovascular events - MACE; ventricular arrhythmias; hospital admissions for heart failure; left ventricular systolic and diastolic disfunction; MACE in special subgroups of patients - elderly, diabetes mellitus, chronic kidney disease).
Aims~heart rate variability (HRV) assessment in patients with acute myocardial infarction who undergo primary percutaneous coronary intervention (PCI);~measurement of HRV using a device approved for medical use in Europe;~assessment of the correlation between HRV and short- and long-term adverse cardiovascular events (composite of all-cause mortality and major adverse cardiovascular events - MACE; ventricular arrhythmias; hospital admissions for heart failure; left ventricular systolic and diastolic disfunction; MACE in special subgroups of patients - elderly, diabetes mellitus, chronic kidney disease) in patients treated by primary PCI for acute myocardial infarction;~creating a registry of HRV parameters measured in a contemporary cohort of patients with acute myocardial infarction.